Unlock AI, break data silos,
and protect privacy with our Federated Learning software
Owkin Connect provides the infrastructure and AI technology that open the possibility for an unprecedented breadth of collaboration in healthcare while protecting patient privacy and data governance. Our distributed architecture and federated learning capabilities allow data scientists to securely connect to decentralised, multi-party datasets and train AI models without having to pool data. Data remains local, only algorithms travel.Get in touch
Aggregate models & insights, not data:
Owkin Connect technology is centered on three core principles — collaboration, confidentiality, and compliance. Life science companies deploy Owkin Connect in a wide variety of settings for clinical research, drug discovery and development.
Expand access to connected partner data
Meet global compliance requirements
Owkin Connect is used in collaborative and competitive settings, when protecting confidential, proprietary or sensitive data and insights extracted from the data through the models are essential.
How Owkin Connect works
Owkin Connect is currently deployed and operating multiple federated networks
around the world, including:
Unparalleled collaboration between pharma competitors in Drug Discovery
Now more than ever innovation and optimization are crucial to increase the pharmaceutical industry’s productivity and sustainability. The MELLODDY Project, a three-year, multi-million euro and 17 partner large research study funded by the IMI 2 Joint Undertaking, has set out to understand how competitive parties in collaboration can benefit from joint machine learning efforts at scale on pre-clinical datasets.
The endeavor has the potential to accelerate drug discovery, without compromising proprietary information or data privacy. Enabling Federated Learning for the MELLODDY project, Owkin Connect helped to secure the first Federated Learning model for drug discovery at scale. Owkin’s proprietary structure has been audited and has been deployed at 10 pharmaceutical companies.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831472. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Breast Cancer Treatment Evaluation with Owkin Connect
Alongside clinical, research, and technology partners we established that machine learning models can be trained successfully on histology images, siloed at different clinical centers, to predict treatment responses in breast cancer. The model trained with Owkin Connect can help oncologists to choose the most effective breast cancer treatment for each patient based on a single biopsy. Learn more about the HealthChain project here.
Image caption: In January 2020, Connect enabled the first-ever federated deep learning model trained on distributed histology images stored behind hospital firewalls.